Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hyperprogressive disease in patients receiving immune checkpoint inhibitors.

Current problems in cancer - 1 Jun 2021

Zhang Haochen, Fang Xuefeng, Li Dan, Yang Mengyuan, Yu Linzhen, Ding Yuwei, Shen Hong, Yuan Ying

Abstract excerpt

Hyperprogressive disease (HPD) is an unexpected response pattern observed in immune checkpoint therapy and associated with poor prognosis in several cancers. Such patients can't benefit from immunotherapy and even experience a rapid disease progression. At present, many researchers have explored the HPD phenomenon, but there is no consensual definition of HPD in different studies. The incidence of HPD is about...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Prognosis

Source

Identifiers

PMID: 33334611
DOI: 10.1016/j.currproblcancer.2020.100688

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hyperprogressive disease in patients receiving immune checkpoint inhibitors.PMID 33334611Read ↗

Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).Semantic proximity Read ↗

Pseudoprogression in Immunotherapy and Identification of Clinical-Biologic Predictive Factors: A Retrospective Pan-Tumor Cohort StudySemantic proximity Read ↗

Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy.Semantic proximity Read ↗

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for CancerSemantic proximity Read ↗

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read ↗

Hypermutated Tumors and Immune Checkpoint Inhibition.Semantic proximity Read ↗

Based on Immune Microenvironment and Genomic Status, Exploring Immunotherapy in Advanced Hidradenocarcinoma: A Retrospective Analysis.Semantic proximity Read ↗

Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs)Semantic proximity Read ↗

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics.Semantic proximity Read ↗

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read ↗

Homologous Recombination Deficiency as a Novel Therapeutic Target in Various Solid TumorsSemantic proximity Read ↗

Immune Checkpoint Inhibitors to Treat Malignant LymphomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.